Next Article in Journal
How I Manage Frontline Transplant-Eligible Multiple Myeloma in Italy
Previous Article in Journal
The Curious Case of Hemoglobin DC Disease Masquerading as Sickle Cell Anemia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 12
Issue s1
10.4081/hr.2020.8956
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Conference Report

How I Manage Frontline Transplant-Ineligible Multiple Myeloma

by
Daniele Derudas
1,*,
Francesca Capraro
1,
Giovanni Martinelli
2 and
Claudio Cerchione
2
1
S.C. di Ematologia e C.T.M.O., Ospedale Oncologico di Riferimento Regionale “A. Businco”, via Jenner snc, 09121 Cagliari, Italy
2
Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2020, 12(s1), 8956; https://doi.org/10.4081/hr.2020.8956
Submission received: 21 September 2020 / Revised: 21 September 2020 / Accepted: 21 September 2020 / Published: 21 September 2020

Abstract

The Multiple Myeloma (MM) is a plasma cells hematological malignancy with a median age of 69 years at diagnosis. The autologous stem cell transplantation is the standard of care for this disease but less than half of newly diagnosed patients are assessed for this treatment due to comorbidities or complications of disease. The management of transplant ineligible MM patients is based on the balance safety and efficacy of the new available regimen and a careful assessment of the frailty status is mandatory to define the goals. In this review we discuss of the clinical dilemmas in the management and define how to manage them based on the evidence from clinical trials and “real life” experience.
Keywords: Multiple Myeloma; transplant-ineligible Multiple Myeloma; transplant-ineligible

Share and Cite

MDPI and ACS Style

Derudas, D.; Capraro, F.; Martinelli, G.; Cerchione, C. How I Manage Frontline Transplant-Ineligible Multiple Myeloma. Hematol. Rep. 2020, 12, 8956. https://doi.org/10.4081/hr.2020.8956

AMA Style

Derudas D, Capraro F, Martinelli G, Cerchione C. How I Manage Frontline Transplant-Ineligible Multiple Myeloma. Hematology Reports. 2020; 12(s1):8956. https://doi.org/10.4081/hr.2020.8956

Chicago/Turabian Style

Derudas, Daniele, Francesca Capraro, Giovanni Martinelli, and Claudio Cerchione. 2020. "How I Manage Frontline Transplant-Ineligible Multiple Myeloma" Hematology Reports 12, no. s1: 8956. https://doi.org/10.4081/hr.2020.8956

APA Style

Derudas, D., Capraro, F., Martinelli, G., & Cerchione, C. (2020). How I Manage Frontline Transplant-Ineligible Multiple Myeloma. Hematology Reports, 12(s1), 8956. https://doi.org/10.4081/hr.2020.8956

Article Metrics

Back to TopTop